Who are D. Midazolam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Remifentanil and/or propofol, propofol (drug), Sevoflurane, Sufentanil, Stiripentol Oral Capsule, Auris-Sedina, SAGE-547.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/d-midazolam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

D. Midazolam — Competitive Intelligence Brief

D. Midazolam (D. Midazolam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine. Area: Oncology.

phase 2 Benzodiazepine GABA_A receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

D. Midazolam (D. Midazolam) — Paion UK Ltd.. GABA_A receptor agonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
D. Midazolam TARGET	D. Midazolam	Paion UK Ltd.	phase 2	Benzodiazepine	GABA_A receptor
Remifentanil and/or propofol	Remifentanil and/or propofol	Alder Hey Children's NHS Foundation Trust	phase 3	Opioid analgesic, Sedative-hypnotic	Opioid receptors, GABA_A receptor
propofol (drug)	propofol (drug)	B. Braun Melsungen AG	phase 3	GABA receptor agonist	GABA_A receptor
Sevoflurane, Sufentanil	Sevoflurane, Sufentanil	University of Saskatchewan	phase 3	General anesthetic, Opioid analgesic	GABA_A receptor, Mu-opioid receptor
Stiripentol Oral Capsule	Stiripentol Oral Capsule	Biocodex	phase 3	GABA_A receptor modulator	GABA_A receptor
Auris-Sedina	Auris-Sedina	Laboratorios Osorio de Moraes Ltda.	phase 3	Benzodiazepine	GABA_A receptor
SAGE-547	SAGE-547	Supernus Pharmaceuticals, Inc.	phase 3	antisense oligonucleotide	GABA_A receptor alpha 1 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzodiazepine class)

Hamad Medical Corporation · 3 drugs in this class
Lundbeck LLC · 2 drugs in this class
UCB Biopharma SRL · 2 drugs in this class
Universitaire Ziekenhuizen KU Leuven · 2 drugs in this class
Bausch Health · 1 drug in this class
Centro Medico Nacional La Raza, IMSS · 1 drug in this class
Assaf-Harofeh Medical Center · 1 drug in this class
Daegu Catholic University Medical Center · 1 drug in this class
B.P. Koirala Institute of Health Sciences · 1 drug in this class
Consorci Sanitari de l'Anoia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). D. Midazolam — Competitive Intelligence Brief. https://druglandscape.com/ci/d-midazolam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab